NEW YORK–(BUSINESS WIRE)–AccurKardia, an innovator in ECG-based diagnostics technology, has announced the initiation of a multicenter clinical pilot of AK+ GuardTM, an FDA Breakthrough Device Designated AI-powered technology that enables the detection of hyperkalemia using Lead I ECG. The three-arm prospective pilot study will evaluate more than 150 patients across inpatient, outpatient and home settings in the U.S.
AccurKardia Announces Clinical Pilot Study of Its AK+ Guard ECG-based, AI-powered Hyperkalemia Detection Software
